A novel class of antibiotics for treatment of infected atopic dermatitis: an innovative solution for a significant unmet medical need

Projektinformationen

ATx201

ID Finanzhilfevereinbarung: 736508

DOI

10.3030/736508

Projekt abgeschlossen

EK-Unterschriftsdatum 11 Juli 2016

Startdatum 1 August 2016

Enddatum 30 November 2016

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

UNION THERAPEUTICS AS
Denmark

Periodic Reporting for period 1 - ATx201 (A novel class of antibiotics for treatment of infected atopic dermatitis: an innovative solution for a significant unmet medical need)

Berichtszeitraum: 2016-08-01 bis 2016-11-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Atopic dermatitis (AD) is associated with significant co-morbidity. The solution provided by AntibioTx represents a new mode of action. The objectives of the project are to verify the promise of the drug product and advance commercial understanding to bring the solution to market.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

The current stage of development of the proposed solution aligns with a Technology Readiness Level 7 since the drug compound had been tested on human subject volunteers. The project helped to establish the definition development plans for the solution in questions. This includes assessment of regulatory route, interaction with regulatory consultants and competent authorities, as well as clinical study design to bring forward its market authorisation agenda. This process has been developed with clinical advisors and KOLs within dermatology.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

The project is designed to demonstrate how the solution in question can contribute to address the medical need in atopic dermatitis and offer a better treatment due to the new mode of action. Early data provides evidence for the potential to change the treatment paradigm of dermatological diseases by providing an innovative and significantly differentiated treatment.

fotolia-114431753-subscription-monthly-m.jpg

boksbillede1.jpg